In short
Clinical trials are investigating LYSERGIDE in different patient groups to see whether it can help with symptoms and whether it is safe and effective in study settings. The trials in this article include adults with generalized anxiety disorder, chronic cluster headache, and attention deficit hyperactivity disorder (ADHD).
Key points
- Clinical trials investigating LYSERGIDE are studying different adult patient groups, including people with generalized anxiety disorder, chronic cluster headache, and ADHD. The trials are in Phase 2 and Phase 3, so they are testing both early signals of benefit and larger comparisons with placebo. One Phase 3 study is measuring anxiety symptoms with the HAM-A scale, while Phase 2 studies are looking at headache attack frequency and ADHD-related outcomes. The studies use designs such as double-blind, placebo-controlled, randomized, and open-label extension formats. One ADHD trial was withdrawn, while the other two listed trials are authorised. Overall, the trial data focus on whether the study treatments can improve symptoms and how well they can be measured over time.
Trial overview
The trial data show three interventional studies investigating LYSERGIDE-related treatments in adults with different conditions. Two studies are authorised, and one study was withdrawn.
The studies are in Phase 2 and Phase 3, which means they are testing whether the study treatments may help symptoms and how they compare with placebo in larger or smaller groups.
Generalized anxiety disorder study
NCT06809595 is a Phase 3, double-blind, placebo-controlled study with an open-label extension for adults with Generalized Anxiety Disorder (GAD). The study is authorised and plans to enroll 375 participants.
In Part A, the main goal is to compare a single dose of 100 μg MM120 with placebo to see whether anxiety symptoms improve. The main outcome is the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12.
This means the study is measuring whether anxiety scores go down over time in the group receiving the study treatment compared with the placebo group.
Chronic cluster headache study
NCT05477459 is a Phase 2 randomized placebo-controlled study in adults with chronic cluster headache. It is authorised and plans to enroll 52 participants.
The study is evaluating the efficacy and safety of minidosing lysergic acid diethylamide (LSD) 25 μg every 3 days for 3 weeks, compared with placebo. The primary outcome is the mean change in weekly attack frequency in the third treatment week compared with the 4-week baseline.
This endpoint focuses on whether the number of headache attacks changes during treatment, which is a practical way to measure possible benefit for patients.
ADHD and emotion regulation study
The third trial, 2025-520906-36-00, is a Phase 2 interventional study in adults with Attention Deficit Hyperactivity Disorder (ADHD). It was planned to enroll 120 participants but is now withdrawn.
The brief summary says the study aimed to investigate whether microdosing with a serotonergic agent, given as 20 mcg of LSD, may improve core ADHD symptoms, emotional regulation, and sleep. The primary outcomes listed are ADHD symptoms, emotion regulation, and sleep.
This trial was designed to look beyond attention symptoms alone and see whether daily life areas such as emotion control and sleep could also change.
Study designs and endpoints
Across the trial data, the studies use common clinical research designs such as double-blind, placebo-controlled, and randomized methods.
These designs help compare the study treatment with placebo in a fair way and reduce the chance that expectations affect the results.
The main endpoints differ by condition: anxiety score change for GAD, weekly headache attack frequency for chronic cluster headache, and ADHD symptoms with emotion regulation and sleep for the ADHD study.
Who can participate
The target populations in these trials are adults with the condition being studied. That includes adults with generalized anxiety disorder, chronic cluster headache, or ADHD.
Because each study has its own rules, the exact participation criteria are not fully listed in the trial data provided here.
Key terms used in the trials
Open-label extension means that after the blinded part of the study, participants and researchers know what treatment is being used.
Baseline means the starting point before treatment, which is used to compare later results.
Primary outcome means the main result the study is designed to measure.
Weekly attack frequency means the number of headache attacks in one week.
Emotion regulation means how well a person can manage and respond to emotions in daily life.